Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radiolabelled GSK189075 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Radiolabelled GSK189075 | DRUG | - |
Inclusion Criteria: * Are a healthy, non-smoking male. * Are 30 to 55 years old, inclusive. * Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight \>110 lbs. * Have a history of regular bowel movements (at least 4 times per week). * Are willing and able to provide written ...
Radiolabelled GSK189075 is an investigational small molecule being studied for Type 2 Diabetes Mellitus. It is a radiolabelled form of GSK189075, intended for use in a clinical trial to track the drug's behavior in the body. It is in Phase 1 clinical development and is not yet approved.
Radiolabelled GSK189075 is being developed by GSK plc, traded on the stock exchange under the ticker GSK. The company is conducting clinical research on this investigational drug for the treatment of Type 2 Diabetes Mellitus.
Radiolabelled GSK189075 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
Radiolabelled GSK189075 has one completed clinical trial, identified as NCT00501683. This Phase 1 study, titled 'A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers,' enrolled 8 participants in the United States.
Radiolabelled GSK189075 is a radiolabelled version of GSK189075, meaning it contains a small amount of radioactivity for tracking purposes in clinical studies. It is used to study the pharmacokinetics of GSK189075 in the body, specifically in a Phase 1 trial involving healthy male volunteers.